We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion
Read MoreHide Full Article
Pacira BioSciences, Inc. (PCRX - Free Report) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on its marketed product Exparel and recommended marketing authorization for the same to treat postsurgical pain in children aged six years and above.
The CHMP recommended approval for Exparel as a field block to treat somatic post-operative pain from small to medium-sized surgical wounds in children aged six years and older.
A final decision from the European Commission (“EC”) on the marketing authorization application for the label expansion of Exparel is expected in November 2022.
Shares of Pacira have lost 8.6% this year so far compared with the industry’s decline of 25.1%.
Image Source: Zacks Investment Research
We remind investors that the EC granted marketing authorization to Exparel as a brachial plexus block or femoral nerve block for treating postoperative pain in adults and as a field block for the treatment of somatic post-operative pain from small to medium-sized surgical wounds in adults in November 2020.
Following the nod, Exparel became the first long-acting non-opioid option for field block and brachial plexus or femoral nerve block approved in Europe.
Exparel, a liposome injection of bupivacaine, is indicated for a single-dose administration into the surgical site to produce postsurgical analgesia for patients in the United States.
In March 2021, the FDA approved Pacira’s supplemental new drug application seeking approval of Exparel for use in children aged six years and above.
Pacira’s flagship product Exparel has witnessed a strong uptake since its launch and has been its constant revenue driver thereafter. The drug generated sales worth $266.2 million in the first six months of 2022, reflecting an increase of almost 8.7% year over year.
Successful label expansion of Exparel into additional indications is likely to boost sales further in the days ahead.
Aptose Biosciences’ loss per share estimates has narrowed 14% for 2022 and 10% for 2023 in the past 60 days.
Earnings of Aptose Biosciences surpassed estimates in three of the trailing four quarters and missed the same on the remaining occasion. APTO delivered an earnings surprise of 2.23%, on average.
Atara Biotherapeutics’ loss per share estimates has narrowed 43.2% for 2022 and 21.3% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics surpassed estimates in three of the trailing four quarters and missed the mark on a single occasion. ATRA delivered an earnings surprise of 4.83%, on average.
ORIC Pharmaceuticals’ loss per share estimates has narrowed 8.6% for 2022 and 22% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed the same on the remaining occasion. ORIC delivered an earnings surprise of 8.85%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion
Pacira BioSciences, Inc. (PCRX - Free Report) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on its marketed product Exparel and recommended marketing authorization for the same to treat postsurgical pain in children aged six years and above.
The CHMP recommended approval for Exparel as a field block to treat somatic post-operative pain from small to medium-sized surgical wounds in children aged six years and older.
A final decision from the European Commission (“EC”) on the marketing authorization application for the label expansion of Exparel is expected in November 2022.
Shares of Pacira have lost 8.6% this year so far compared with the industry’s decline of 25.1%.
Image Source: Zacks Investment Research
We remind investors that the EC granted marketing authorization to Exparel as a brachial plexus block or femoral nerve block for treating postoperative pain in adults and as a field block for the treatment of somatic post-operative pain from small to medium-sized surgical wounds in adults in November 2020.
Following the nod, Exparel became the first long-acting non-opioid option for field block and brachial plexus or femoral nerve block approved in Europe.
Exparel, a liposome injection of bupivacaine, is indicated for a single-dose administration into the surgical site to produce postsurgical analgesia for patients in the United States.
In March 2021, the FDA approved Pacira’s supplemental new drug application seeking approval of Exparel for use in children aged six years and above.
Pacira’s flagship product Exparel has witnessed a strong uptake since its launch and has been its constant revenue driver thereafter. The drug generated sales worth $266.2 million in the first six months of 2022, reflecting an increase of almost 8.7% year over year.
Successful label expansion of Exparel into additional indications is likely to boost sales further in the days ahead.
Zacks Rank & Stocks to Consider
Pacira currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Aptose Biosciences Inc. (APTO - Free Report) , Atara Biotherapeutics, Inc. (ATRA - Free Report) and ORIC Pharmaceuticals, Inc. (ORIC - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aptose Biosciences’ loss per share estimates has narrowed 14% for 2022 and 10% for 2023 in the past 60 days.
Earnings of Aptose Biosciences surpassed estimates in three of the trailing four quarters and missed the same on the remaining occasion. APTO delivered an earnings surprise of 2.23%, on average.
Atara Biotherapeutics’ loss per share estimates has narrowed 43.2% for 2022 and 21.3% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics surpassed estimates in three of the trailing four quarters and missed the mark on a single occasion. ATRA delivered an earnings surprise of 4.83%, on average.
ORIC Pharmaceuticals’ loss per share estimates has narrowed 8.6% for 2022 and 22% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed the same on the remaining occasion. ORIC delivered an earnings surprise of 8.85%, on average.